EUCTR2012-003324-20-Outside-EU/EEA进行中（未招募）不适用
An open-label study to assess the immune persistence in healthy Chinese toddlers primed in infancy with three doses of GSK Biologicals’ DTPa-IPV/Hib vaccine, and to assess the safety and immunogenicity of a booster dose of IPV and DTPa/Hib administered at 18 to 24 months of age. - DTPA-IPV (INFANRIX-IPV)-057 BST: 056
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 831
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A male or female child between, and including, 18 and 24 months of age at the time of the booster vaccination.
- •Subjects who completed the full three-dose primary vaccination course in the DTPA-IPV-056 (112584) study.
- •Subjects who the investigator believes that their parent(s)/ LAR(s) can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for the follow-up visit).
- •Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 831
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Child in care.
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the booster dose of the study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose. For corticosteroids, this will mean prednisone >= 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- •Administration of a vaccine not foreseen by the study protocol within 30 days prior to the booster vaccination, or planned administration during the study period.
- •Participation in another clinical study within three months prior to enrolment in the present booster study or at any time during the present booster study, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •Evidence of previous diphtheria, tetanus, pertussis, poliomyelitis and Hib, vaccination or disease since the con-clusion visit of primary study DTPA-IPV-056 (112584).
- •Serious chronic illness.
- •Administration of immunoglobulins and/or any blood products within the 90 days preceding the booster dose of study vaccine or planned administration during the study period.
- •Occurrence of any of the following adverse events (AEs) after a previous administration of a DTP vaccine.
- •-Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination and generally consisting of major alterations in consciousness, unresponsiveness, generalised or focal seizures that persist more than a few hours, with failure to recover within 24 hours.
- •-Temperature of = 40.0°C (axillary temperature) within 48 hours of vaccination, not due to another identifiable cause.
- •-Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
- •-Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting = 3 hours.
- •-Seizures with or without fever occurring within 3 days of vaccination.
- •The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:
- •Acute disease and/or fever at the time of enrolment.
- •-Fever is defined as temperature = 37.1°C on oral, axillary or tympanic setting, or = 37.6°C on rectal setting. The preferred route for recording temperature in this study will be axillary.
- •Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
研究者
相似试验
进行中（未招募）
不适用
Study to evaluate immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ Inactivated Polio Vaccine (Poliorix) in healthy Chinese toddlers.Booster immunisation of healthy children in the second year of life against poliomyelitis.EUCTR2012-004513-14-Outside-EU/EEAGlaxoSmithKline Biologicals957
进行中（未招募）
不适用
Immunogenicity and safety study of GSK Biologicals’ Infanrix-IPV+Hib™ vaccine.Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases.EUCTR2011-005868-25-Outside-EU/EEAGlaxoSmithKline Biologicals985
进行中（未招募）
不适用
Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ inactivated polio vaccine (Poliorix) in infants.Primary immunisation of healthy infants in the first year of life against poliomyelitisEUCTR2011-003167-30-Outside-EU/EEAGlaxoSmithKline Biologicals1,101
进行中（未招募）
不适用
An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Aged 18 to 59 Years - Phase I/II Study of a H5N1 VaccineEUCTR2008-005133-30-ATBaxter Innovations GmbH230
进行中（未招募）
不适用
An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Aged 18 to 59 Years - Phase I/II Study of a H5N1 VaccineH5N1 vaccination with a single Prime-Boost Vaccination schedule in healthy subjects aged 18 to 59 years.MedDRA version: 9.1Level: LLTClassification code 10059430Term: Influenza immunizationEUCTR2008-005133-30-FIBaxter Innovations GmbH230